Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

3.480 +0.630 (+22.11%)
Streaming Delayed Price Updated: 1:01 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eledon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
80 Participants (Two-thirds of Projected Recruitment) Enrolled 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets. 
Via InvestorPlace
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly. 
Via InvestorPlace
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Expert Ratings for Eledon Pharma
 
Via Benzinga
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ... 
Via Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.